Accelerating Human Health Through Frontier Research
Zenth Health Sciences R&D spans 14 global innovation centers, driving breakthroughs in gene therapy, AI-driven drug discovery, regenerative medicine, and next-generation diagnostics.
Core Discovery Areas
Our multidisciplinary teams focus on high-impact therapeutic domains where science, technology, and clinical expertise converge.
Genomic Medicine
CRISPR-based therapeutics, base editing, and multi-omics profiling for precision treatment stratification across oncology and rare diseases.
Neurotechnology
Next-gen neurostimulation, blood-brain barrier penetration platforms, and AI-driven neuroimaging for Alzheimer's, Parkinson's, and spinal disorders.
Immunotherapy & Cell Engineering
Off-the-shelf CAR-T/NK cells, bispecific antibodies, and mRNA-based cancer vaccines with proprietary antigen presentation algorithms.
AI-Driven Drug Discovery
Generative molecular design, quantum-accelerated docking simulations, and predictive toxicity modeling reducing Phase I failure rates by 40%.
Synthetic Biology
Engineered microbial consortia for gut microbiome therapeutics, biomanufacturing of high-value biologics, and programmable biosensors.
Digital Health & Diagnostics
Liquid biopsy platforms, continuous multi-analyte wearables, and federated learning models for real-world evidence generation.
Clinical & Preclinical Programs
Tracking our most advanced therapeutic candidates across global clinical sites.
Lead Assets (2025-2027)
| Program Code | Indication | Mechanism | Stage | Expected Readout |
|---|---|---|---|---|
| ZTH-904 | Solid Tumors | Universal CAR-T | Phase III | Q3 2025 |
| ZTH-812 | Alzheimer's Disease | Antisense Oligo / AΞ² Targeting | Phase II | Q1 2026 |
| ZTH-775 | Type 1 Diabetes | Encapsulated Beta-Cell Islet Therapy | Phase I | Q4 2025 |
| ZTH-699 | CFTR Mutations | MRNA Gene Correction | Preclinical | IND Submission Q2 2025 |
| ZTH-621 | Sepsis / MODS | Recombinant Immune Modulator | Phase II | Q2 2026 |
Innovation & Manufacturing Centers
Purpose-built facilities spanning discovery, GMP manufacturing, and clinical operations.
Advance the Future of Medicine Together
We partner with academic institutions, biotech startups, and global health organizations to de-risk early-stage research and accelerate patient access.